drugset / Trial / NCT01699737

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737

Phase 2 Completed 325 enrolled Akros Pharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.

Timeline

Start
2012-09
Primary completion
2013-05
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule Oral
Subject JTT-851 Unknown Oral